Puma Biotechnology INC (PBYI) Holder Ascend Capital LLC Raised Stake

Investors sentiment decreased to 0.99 in Q3 2018. Its down 0.33, from 1.32 in 2018Q2. It is negative, as 29 investors sold PBYI shares while 39 reduced holdings. 19 funds opened positions while 48 raised stakes. 33.41 million shares or 10.98% less from 37.53 million shares in 2018Q2 were reported. Pictet Asset Mngmt Ltd has invested 0.04% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Jane Street Gru Ltd Com holds 0% or 16,944 shares in its portfolio. Boston Advisors Ltd Liability Co reported 0.03% in Puma Biotechnology, Inc. (NASDAQ:PBYI). D E Shaw invested 0.01% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Parametric Portfolio Limited Liability Corp stated it has 48,129 shares. Automobile Association accumulated 0% or 4,673 shares. Bancorporation Of Montreal Can has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Gp One Trading LP stated it has 26,674 shares or 0.01% of all its holdings. Sio Limited Company has 32,832 shares for 0.52% of their portfolio. Engaged Lc owns 151,689 shares. Sei Invs Communication stated it has 756 shares or 0% of all its holdings. Synovus Financial Corp, Georgia-based fund reported 23 shares. Credit Suisse Ag owns 22,311 shares or 0% of their US portfolio. Moreover, Us Bankshares De has 0% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 100 shares. Clear Harbor Asset Mngmt Limited Liability reported 0.09% stake.

Since July 20, 2018, it had 0 buys, and 8 sales for $1.04 million activity. Shares for $95,360 were sold by Lo Steven on Friday, July 20. 1,210 shares were sold by BRYCE RICHARD PAUL, worth $25,011 on Thursday, January 3. $91,444 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) was sold by AUERBACH ALAN H.

Ascend Capital Llc increased its stake in Puma Biotechnology Inc (PBYI) by 1093.43% based on its latest 2018Q3 regulatory filing with the SEC. Ascend Capital Llc bought 656,662 shares as the company’s stock declined 49.57% with the market. The hedge fund held 716,717 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $85.83M, up from 60,055 at the end of the previous reported quarter. Ascend Capital Llc who had been investing in Puma Biotechnology Inc for a number of months, seems to be bullish on the $870.62M market cap company. The stock decreased 2.39% or $0.56 during the last trading session, reaching $22.83. About 308,835 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has declined 77.02% since January 14, 2018 and is downtrending. It has underperformed by 77.02% the S&P500.

Ascend Capital Llc, which manages about $4.98B and $2.65B US Long portfolio, decreased its stake in Dxc Technology Co by 136,582 shares to 164,068 shares, valued at $14.09 million in 2018Q3, according to the filing. It also reduced its holding in Raytheon Co (NYSE:RTN) by 79,029 shares in the quarter, leaving it with 27,689 shares, and cut its stake in Siteone Landscape Supply Inc.

More notable recent Puma Biotechnology, Inc. (NASDAQ:PBYI) news were published by: Benzinga.com which released: “Daily Biotech Pulse: Ampio Slides On Offering, Sangamo’s Positive Trial Results, Insys Earnings – Benzinga” on August 09, 2018, also Streetinsider.com with their article: “After-Hours Movers (MRIN) (PBYI) (ORCL) Higher (more…) – StreetInsider.com” published on December 17, 2018, 247Wallst.com published: “Can Puma Biotechnology Break In to Europe? – 24/7 Wall St.” on June 26, 2018. More interesting news about Puma Biotechnology, Inc. (NASDAQ:PBYI) were released by: Nasdaq.com and their article: “Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? – Nasdaq” published on May 03, 2017 as well as Investorplace.com‘s news article titled: “10 Stocks Ready for a BIG Move – In Either Direction – Investorplace.com” with publication date: June 15, 2017.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Ratings Coverage

Among 6 analysts covering Puma Biotechnology (NYSE:PBYI), 2 have Buy rating, 2 Sell and 2 Hold. Therefore 33% are positive. Puma Biotechnology had 9 analyst reports since August 10, 2018 according to SRatingsIntel. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Overweight” rating by JP Morgan on Friday, August 10. The company was maintained on Friday, November 2 by Cantor Fitzgerald. The company was maintained on Tuesday, September 18 by Citigroup. The company was downgraded on Thursday, January 3 by Guggenheim. The rating was downgraded by Barclays Capital on Friday, November 2 to “Underweight”. The rating was downgraded by JP Morgan to “Underweight” on Friday, November 2. On Monday, November 19 the stock rating was upgraded by Goldman Sachs to “Neutral”.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.